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A B S T R A C T
Here, we describe the development of a Dutch national guideline on metastases and hematological malignancies
localized within the spine. The aim was to create a comprehensive guideline focusing on proactive management
of these diseases, enabling healthcare professionals to weigh patient perspectives, life expectancy, and expected
outcomes to make informed treatment recommendations. A national multidisciplinary panel consisting of
clinicians, a nurse, a patient advocate, an epidemiologist, and a methodologist drafted the guideline. The im-
portant role of patients in the realization of the guideline enabled us to identify and address perceived short-
comings in patient care. The guideline covers not only metastatic epidural spinal cord compression, but also the
treatment of uncomplicated metastases and hematological malignancies localized within the spine. The guide-
line is applicable in daily practice and provides an up-to-date and concise overview of the diagnostic and
treatment possibilities for patients suﬀering from a disease that can have a serious impact on their quality of life.
Suggestions for the practical implementation of patient care in hospitals are also provided, including approaches
for pursuing proactive management. The crucial role of the patient in decision making is emphasized in this
guideline.
Introduction
Global incidence rates of cancer are rising, mainly due to the ageing
population [1,2]. These changes will translate to a predicted 20 million
new cancer cases worldwide by 2030, compared with an estimated 12.7
million cases in 2008 [3,4]. This increased incidence, combined with
the longer survival of patients with cancer, has resulted in more people
being confronted with metastatic disease, in which the skeleton is often
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aﬀected [5–8]. Bone metastases most frequently occur in the spinal
column [9]; postmortem examinations have demonstrated that spinal
metastases are present in approximately 70% of patients with cancer
[10]. More than 50% of spinal metastases are secondary tumors from
breast, lung, or prostate carcinomas [11]. Multiple myeloma and
sometimes lymphomas may also aﬀect the spinal column [12,13].
Spinal metastases and spinal localizations may lead to back pain,
spinal instability, pathological fractures and deformity. Furthermore,
epidural growth or vertebral collapse may cause radiating neuropathic
pain and neurological deﬁcits because of the compression of the spinal
cord or nerve roots, which severely aﬀect the patient’s quality of life.
Consequently, the provision of information for patients, timely diag-
nosis, optimized local and/or systemic treatment, and adequate follow-
up are of the utmost importance in the prevention or reduction of the
progression of spinal metastases towards irreversible neurological da-
mage.
In current clinical practice, the care management of patients with
cancer and metastatic disease, including spinal metastases, is often re-
active, responding to clinical symptoms rather than trying to proac-
tively prevent complications. The optimal diagnosis and management
of patients with spinal metastases requires a multidisciplinary ap-
proach. Although diﬃcult to arrange, this is particularly important in
emergency situations such as metastatic epidural spinal cord compres-
sion (MESCC).
The Dutch health system is a strong proponent of developing
guidelines to reduce the nationwide variability in the treatment of
many diseases. Many guidelines have been developed since the late
1990s, and are revised every ﬁve years [14,15]. These guidelines pro-
vide evidence- and consensus-based recommendations and require-
ments for the standard of care at a national level. Guidelines are also
being developed internationally; for example, the American Society for
Radiation Oncology (ASTRO), the Italian Orthopaedic Society (SIOT),
and the United Kingdom’s National Institute for Health and Care Ex-
cellence (NICE) have developed guidelines regarding the treatment/
management of patients with (spinal) bone metastases [16–19].
In 2013, a national working group started to develop a new
guideline for the treatment of patients with cancer and spinal metas-
tases and patients with hematological malignancies localized within the
spine. Four important principles were deﬁned at the start:
1. The patient’s perspective should lead the discussion. Patients
themselves should have an important role in the decision-making
process (patient participation).
2. Proactive management should be pursued, resulting in a rapid and
adequate diagnosis and treatment and, as much as possible, the
prevention of (the progression of) pain and the occurrence of neu-
rological deﬁcits.
3. Clear selection criteria for various treatments should be deﬁned,
taking into account the patient’s spinal instability, spinal deformity,
neurological prognosis, and life expectancy.
4. The organization, communication, and coordination of care should
be optimized.
This paper describes the main results used in the evidence-based
approach for the development of the Dutch national guideline on me-
tastases and hematological malignancies localized within the spine. In
addition, suggestions for its implementation are discussed, and prac-
tical considerations are provided to enable institutes to pursue the
proactive management and organization of care.
Methods
In 2013, the Dutch Neuro-Oncology Working Group (LWNO), sup-
ported by the Netherlands Comprehensive Cancer Organisation (IKNL),
formed a multidisciplinary expert working group tasked with drafting a
guideline on spinal metastases. Since the symptoms, complications, and
treatments of hematological malignancies in the spine are very similar
to those of spinal metastases arising from solid tumors, both are in-
cluded in this guideline. Here, the term ‘spinal metastases’ includes
spinal localizations of hematologic and solid-tumor malignancies, both
with and without MESCC, unless otherwise speciﬁed.
The members of the working group represented all regions of the
Netherlands, both university and general hospitals, and all relevant
medical disciplines. All working group members were representatives
of their national scientiﬁc associations, and had a mandate for their
input. The working group members had expertise in anesthesiology/
pain medicine, epidemiology, general practice, guideline methodology,
hematology, medical oncology, neurology, neurosurgery, nursing, or-
thopedics, radiology, radiotherapy, and rehabilitation. Most im-
portantly, a patient representative took an active seat in the working
group to provide the patient perspective, and was considered a full
member of the group. In total, the working group comprised 16 mem-
bers. The organizing committee asked the federation of patients for
their participation, which decided to be represented by one person.
A survey was performed amongst both healthcare professionals and
patients to provide an inventory of the perceived bottlenecks in the
various trajectories of patient care. The aim of this ‘bottleneck analysis’
was to provide an overview of all problems or challenges in clinical
practice and, as a consequence, to determine the questions relevant for
clinical practice. The bottleneck analysis was performed following the
methods for developing guidelines outlined by the Dutch health system
[20,21]. A list of these bottlenecks was sent out to all related scientiﬁc
and medical associations and patient organizations in The Netherlands,
asking them to (1) indicate whether they agreed with the identiﬁed
bottlenecks; (2) prioritize the bottlenecks; and (3) indicate whether
they perceived additional bottlenecks. In addition to the bottleneck
inventory, six patients were recruited through the survey and were
interviewed by telephone to gain insights into their perspectives. A total
of 67 individuals responded to the bottleneck analysis, resulting in the
identiﬁcation of 17 bottlenecks in addition to the 15 that were initially
deﬁned. Subsequently, based on the importance assigned to the bot-
tlenecks by the survey respondents and during discussions within the
working group, 14 clinical questions were formulated (Table 1). These
questions were addressed by the working group.
Three clinical questions were addressed using an evidence-based
approach (questions 2, 4, and 5; Table 1). To answer these questions, a
systematic literature search was performed and/or supervised by a lit-
erature researcher/methodology expert. In addition, the methodolo-
gical quality (level of evidence) of the studies was assessed, enabling
the assignment of a level of evidence to the guideline’s conclusions and
recommendations. The work was carried out in accordance with the
Guideline for Guidelines [21]. Question 2 was addressed in accordance
with the Evidence-Based Guideline Development (EBRO) approach, in
which a level of evidence is assigned to each study [22]. The inter-
vention questions (questions 4 and 5) were assessed in accordance with
the Grading of Recommendations Assessment, Development and Eva-
luation (GRADE), in which a pre-deﬁned level of evidence is assigned to
each outcome measure [23]. Consequently, within a single study, one
outcome measure can be categorized as being of high quality, while
another can be assessed as being of low quality. The remaining 11
questions were answered using a consensus-based approach, which in
practice meant that the literature search for these questions was carried
out by the members of the working group themselves.
Each question was allocated to one of the working group members,
based on his or her expertise, who acted as the chair for this issue. In
subgroups of two to four group members, the search strategies and
subsequently retrieved literature were discussed extensively. The ana-
lysis and writing processes for each question were also performed by
the respective subgroup, after which the entire working group discussed
and revised each chapter in plenary meetings. In total, eight plenary
meetings corresponding to approximately 18 h of meeting time were
held to discuss and revise the chapters.
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The patient advocate attended all working group meetings, actively
participated in the discussions, and optimized the formulation of the
patient’s perspective in the draft texts. In addition, the working group
veriﬁed whether the issues reported by the patients were suﬃciently
addressed in the guideline’s conclusions and recommendations.
After approval from all working group members, the draft guideline
was presented to the LWNO. The feedback from the LWNO members
was in turn processed by the working group. The adapted draft guide-
line was then presented for comments to all scientiﬁc and professional
associations and patient organizations that had been contacted within
the framework of the bottleneck analysis, as well as to national and
regional tumor working groups and the National Federation of Cancer
Patient Organizations, resulting in the receipt of 145 comments from 25
respondents. The comments were evaluated and processed by the
guideline working group. Eventually, the guideline was submitted to
the relevant associations/authorities for authorization or approval, and
the ﬁnal guideline was published online in August 2015.
With the help of the patient advocate and a ‘www.kanker.nl’ editor,
the information for patients was written and annexed into the guide-
line. This information is also available at www.kanker.nl [24], a na-
tional website that provides information to patients with cancer.
This paper describes the key outcomes of the guideline. The com-
plete guideline has been translated into English and is freely available
at www.oncoline.nl/spinal-metastases.
Results
This chapter describes the main ﬁndings of the guideline based on
the four principles mentioned above.
The patient perspective
During the bottleneck analysis, patients identiﬁed the following
points for improvement: having a say in their treatment, the lack of
information on spinal metastases available to patients, the lack of
psychosocial care, the value of multidisciplinary consultations, and
delays in the exploration of symptoms that might indicate the presence
of spinal metastases (doctors’ delay). Extensive patient information on
spinal metastases has now been developed and is annexed to the
guideline (Appendix A).
Proactive care management
Preventing unnecessary delay
A randomized trial demonstrated that 3% of 342 patients with
painful radiated spinal metastases eventually show signs of MESCC
[25]. Although the risk of developing neurological deﬁcits is relatively
low, the consequences can be debilitating. Most patients who are still
ambulant at the time of diagnosis retain their ambulatory status if
treatment is started in a timely manner [26]; however, if treatment is
delayed until a patient is already bedridden due to severe neurological
deﬁcits, the chance of this patient regaining their walking ability is
small [26,27]. To prevent progression towards a (complete) spinal cord
injury or cauda equina syndrome as a result of symptomatic MESCC, it
is therefore important to diagnose the patient as early as possible.
Considerable patient and doctor delays are unfortunately not un-
common [27,28], and are an important factor in the development of
neurological deﬁcits and other adverse outcomes that might be pre-
vented by a faster course of action [26,29]. An important goal of the
guideline is therefore to reduce delays caused by either patients or
physicians.
Raising awareness about the symptoms
The guideline describes the symptoms that indicate the presence of
spinal metastases, spinal instability, or myelum or cauda compression.
These so-called ‘alarm symptoms’ are described in Table 2. The working
group considered it vital that patients with bone metastases and their
general practitioners (GPs) are properly informed about the likelihood
of spinal metastases, the alarm symptoms that (urgently) require as-
sessment, and who to contact in such cases. To this end, the working
group developed a patient information sheet about spinal metastases,
including the alarm symptoms and local contact information, which can
be handed out to high-risk patients and their GPs (Appendix B). Of
course, a broad range of healthcare professionals are confronted with
patients with spinal metastases. To facilitate optimal collaboration and
Table 1
Clinical questions formulated based on the results of the bottleneck analysis.
Clinical question Consensus- (CB) or evidence- based
(EB)
1 What criteria must a patient with spinal metastases meet to be eligible for surgery followed by radiotherapy, or radiotherapy alone? CB
2 Which factors should be used to most accurately predict the survival of patients with spinal metastases who are eligible for surgery
and/or irradiation?
EB - EBROa
3 How can the stability of metastatically aﬀected vertebrae be determined in patients with spinal metastases, in view of a possible
stabilizing operation?
CB
4 Which technique (simple versus advanced technology) and radiotherapy dose leads to the best possible outcome for patients with
spinal metastases in terms of pain relief, mobility, morbidity, mortality, and cost?
EB – GRADEb
5 a. Does surgery via an anterior approach or surgery via a posterior approach oﬀer a better outcome in terms of mobility, morbidity,
mortality, complications, and progression-free survival in patients with symptomatic spinal metastases?
b. Does surgery by means of an en bloc resection of the aﬀected vertebra oﬀer a better outcome than removing the vertebra by the
piecemeal method or a partial resection (debulking), in terms of mobility, morbidity, mortality, complications, and progression-free
survival in patients with symptomatic spinal metastases?
EB - GRADE
6 What is the eﬀect of chemotherapy or hormonal therapy on the neurological deﬁcit, pain, and quality of life in patients with spinal
metastases?
CB
7 Which patients with spinal metastases are eligible for percutaneous interventions, such as radiofrequency ablation (RFA) and
vertebroplasty, with a view to reducing symptoms (e.g. pain), in terms of morbidity, complications and mortality?
CB
8 Does the care trajectory in patients with spinal metastases require the involvement of a pain team? CB
9 How can questionnaires (pain score, neurological functional scales) be used systematically in patients with spinal metastases? CB
10 How is the need for psychosocial assistance detected in patients with spinal metastases and how is this assistance oﬀered? CB
11 Is multidisciplinary consultation always necessary for patients with symptomatic spinal metastases and how is this organized? CB
12 Who follows up on the patient (and how)? CB
13 How is an appropriate rehabilitation process established for patients with spinal metastases? CB
14 Does the aftercare trajectory for patients with spinal metastases require the involvement of a rehabilitation specialist? CB
a EBRO: Evidence-Based Guideline Development.
b GRADE: Grading of Recommendations Assessment, Development and Evaluation.
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prevent delays, these healthcare professionals should all be informed
about the guideline and the accompanying patient sheet outlining the
alarm symptoms.
Clear deadlines for diagnosis and treatment
In addition to delays caused by patients, doctors can also delay the
diagnosis and treatment of spinal metastases. The guideline contains
recommendations and sets clear deadlines for imaging studies when
spinal metastases are suspected (Fig. 1). Spinal metastases cannot be
excluded using conventional x-rays, CT scans, or bone scintigraphy
[28,30]; therefore, full spinal column Magnetic Resonance Imaging
(MRI) is the ﬁrst choice for diagnosing patients when there is a clinical
suspicion of spinal metastases. MRI is superior to all other imaging
modalities when it comes to demonstrating spinal metastases and the
compression of the myelum or cauda [31–36]. Both T1- and T2-
weighted images are required to demonstrate spinal metastases and, in
particular, spinal epidural metastases and/or MESCC [31,37,38]. The
deadline for MRI scanning depends on the nature of the patient’s
complaints (Table 3); an MRI should be performed within two weeks
when the patient has only local back pain, or within 12 h if there is a
clinical suspicion of MESCC, to enable treatment to start promptly.
In patients with suspected spinal metastases of an unknown origin,
there is a need to urgently obtain a histological diagnosis before the
treatment can start. The diagnostic timeframe in these patients depends
on their (risk of) neurological deﬁcits (see Fig. 1).
Treatment selection
The guideline extensively addresses a broad range of treatment
modalities for patients with spinal metastases with respect to their ef-
fectiveness on pain and neurological problems, including radiotherapy,
surgery, systemic treatments, and percutaneous interventions. Based on
the available literature, the working group developed a ﬂow diagram
describing the recommended selection of treatments based on the pa-
tient’s estimated survival, estimated spinal (in)stability, and expected
treatment outcome (Fig. 2).
In general, radiotherapy is the ﬁrst choice of treatment in patients
with symptomatic spinal metastases (with pain and/or neurological
deﬁcit), provided that an adequate radiotherapy dose can be given. To
be eligible for surgery, the patient must have a life expectancy of at
least three months, a good clinical situation, and a limited area of da-
mage and/or obstruction. Surgery is the preferred treatment in case of
(1) spinal instability; (2) the recurrence or progression of pain and/or
neurological deﬁcits following radiotherapy or where repeat radio-
therapy is not possible; and/or (3) neurological deterioration under
radiotherapy and corticosteroids. For the treatment of MESCC-induced
neurological deﬁcits, surgery and radiotherapy are equivalent options.
The choice of treatment should be made on the basis of a (ad hoc)
multidisciplinary discussion (see 4.1), and should incorporate patient
preference following the concept of shared decision making. Detailed
information on the types and dosages of radiotherapy and the types of
surgery are described in the guideline.
Systemic treatment is provided as a primary treatment if there is a
high chance of response (e.g. in multiple myeloma and some types of
malignant lymphoma).
Assessing survival
An accurate assessment of life expectancy is required to prevent
both overtreatment (extensive surgery in patients with a short-term
survival expectancy) and undertreatment (forgoing treatment in pa-
tients with prolonged survival); however, two systematic reviews
showed that the assessment of life expectancy by physicians based so-
lely on their clinical experience is inaccurate [39,40].
The literature describes several prognostic models that can be used
as a tool for predicting survival using patient-speciﬁc risk factors. Four
externally validated models including at least the risk factors primary
tumor and performance status were identiﬁed: the Tokuhashi [41], Van
der Linden [25], Bartels [42], and Bollen [11] models. Details of these
prognostic models can be found in Table 4. The accuracy of the To-
kuhashi model is reported to vary greatly [43–47], but the other models
have been shown to permit a reliable assessment of the survival of
patients with symptomatic spinal metastases, with no model being su-
perior to the others [11,48,49].
Assessing spinal (in)stability
The Spinal Instability Neoplastic Score (SINS) is the ﬁrst attempt to
register mechanical instability due to metastatic disease [50]. The SINS
was developed to help physicians gain insight into the degree of spinal
instability using six radiological and clinical components. Although the
SINS is reproducible and has good inter- and intra-observer agreement
[51,52], to date no prospective study has been published validating the
SINS’s predictive power to diﬀerentiate between spinal lesions at risk of
progressive debilitating instability. The use of SINS as an absolute tool
to diﬀerentiate between stable and unstable spines when making the
decision whether or not to perform surgery is not advised in this
guideline. For now, spinal (in)stability is judged clinically and radi-
ologically. It is recommended that all cases involving patients with a
(potentially) unstable spinal column are discussed with a spinal sur-
geon.
Organization of care
Multidisciplinary cooperation
Determining the best treatment for a patient with spinal metastases
is a complex process that requires a multidisciplinary approach.
Multidisciplinary consultation (MC) meetings are mentioned increas-
ingly often in guidelines and indicator sets [15,53,54]. Fitzpatrick et al.
[53] demonstrated that the number of incorrect referrals of patients for
epidural spinal metastasis surgery is reduced when a prior virtual
consultation (by email, telephone, and imaging via the online PACS
system) with the spinal surgeon takes place. Although there is no other
evidence to support the eﬀectiveness of an MC meeting for patients
with spinal metastases, the guideline committee believes such meetings
are essential for the optimal proactive management of patients with
spinal metastases. All patients with symptomatic spinal metastases
should be discussed in an MC meeting involving a representative of the
original treating medical specialty (e.g., medical oncologist, hematol-
ogist), a radiation oncologist, a radiologist, a neurologist or neuro-on-
cologist (in case of neurological deﬁcits), and (in cases with a potential
Table 2
Alarm symptoms that indicate the presence of spinal metastases, spinal instability, and/or myelum or cauda compression.
Symptoms indicating the presence of spinal metastases in patients with cancer Symptoms indicating spinal instability and/or myelum or cauda compression
– New and/or increasing severe back or neck pain – Decreased strength in the legs (and sometimes the arms)
– Pain between or just below the shoulder blades – Diﬃculty controlling the legs (and sometimes the arms)
– Back pain when lying down (during sleep) that disappears when sitting up – A very wobbly gait
– Radiating pain in the stomach, chest, arms or legs – Numbness or tingling radiating down from chest, stomach, groin, and/or legs
– Inability to walk and/or stand, or legs giving way
K.H.J. Groenen et al. Cancer Treatment Reviews 69 (2018) 29–38
32
Fig. 1. Flowchart on diagnostics in patients with suspected spinal metastases or spinal localization of hematological malignancies. CT: Computed Tomography;
MESCC: Metastatic Epidural Spinal Cord Compression; MRI: Magnetic Resonance Imaging; PET: Positron Emission Tomography.
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need for surgery) a spinal surgeon. This consultation can take place
during a weekly structured MC meeting, but in urgent cases such as a
patient with a progressive neurological deﬁcit, an ad hoc consultation
with at least the responsible physician, a radiation oncologist, and a
spinal surgeon is required.
Optimal palliative care
With the exception of malignancies that can be cured using che-
motherapy (e.g. non-Hodgkin lymphomas), most patients with spinal
metastases are in the palliative phase of their disease. According to the
World Health Organization, palliative care is an approach that im-
proves the quality of life of patients and their families facing the pro-
blems associated with life-threatening illness through the prevention
and relief of suﬀering, by means of the early identiﬁcation and im-
peccable assessment and treatment of pain and other physical, psy-
chosocial, and spiritual problems [55]. Such care involves a substantial
change in the way patients and their relatives are approached. The
current palliative care guideline emphasizes that attention should be
paid to all aspects of care: physical, psychological, social, and spiritual
[56].
In addition, the potential for appropriate actions to be taken to
achieve optimal functionality should be investigated, taking into ac-
count the patient’s wishes and life expectancy. The possibilities to (re)
gain function by means of, for example, a rehabilitation program,
physical therapy, or occupational therapy should therefore be explored.
Coordination of care and communication
The coordination of care and the optimal communication between
all healthcare professionals is essential for the best possible care for
patients with spinal metastases. It is therefore vital to designate the
responsible physician, i.e. the clinician who is the ﬁrst point of contact
for the patient and other care providers, who also controls and co-
ordinates the care provided to the patient. In the disease oriented phase
of care, this will often be a medical specialist in the hospital, such as a
medical oncologist or hematologist. During symptom-oriented phase of
care, the responsibility increasingly shifts to the GP or geriatric spe-
cialist. The principal care provider will ensure a proper, preferably
verbal and written, transfer of care for this transition of responsibility,
which may involve a transfer within the hospital or a transfer from the
hospital specialist to a GP. Patients should be well aware of who their
responsible physician is at all times.
Ideally, the patient’s GP should play a central role, and therefore be
actively involved in the care trajectory as early as possible. Ensuring the
GP is well-informed of the situation at all times is therefore desirable,
including the knowledge of which vertebrae are aﬀected (the results of
most recent diagnostic imaging), what symptoms can be expected, what
to do in case of such symptoms, and the possible options for treatment.
In complex situations, a palliative care team should be available for
consultation by the GP or specialist at all times.
Discussion
The Dutch national guideline on spinal metastases from solid tumors
and hematological malignancies not only focuses on treatment choices,
but also addresses important topics such as proactive care to prevent of
complications, proper patient categorization using predictive models,
multidisciplinary collaboration, and the optimal organization of care,
all based on the needs and wishes of the patient.
Discrepancies often exist between the best clinical practices de-
termined by scientiﬁc evidence and the actual care provided to patients;
about 30–40% of patients do not receive care based on the current
scientiﬁc evidence, and about 20–25% of the care provided is un-
necessary or even potentially harmful to patients [57]. Clinical guide-
lines aim to standardize and improve patient care by providing re-
commendations for appropriate and optimal care in speciﬁc clinical
circumstances, based on an integration of clinical expertise, the best
evidence available, and patient wishes. Understanding the factors that
facilitate or hinder changes in clinical practice can allow implementa-
tion strategies to be tailored for use, and could help to bridge the gap
between scientiﬁc evidence and patient care [58]. Therefore, below
some additional comments are made on the issues raised in the
guideline.
The proactive management of care is targeted by reducing the de-
lays in the diagnosis and treatment of spinal metastases caused by both
doctors and patients. The guideline emphasizes that this delay can be
handled on two levels, both by increasing patient and doctor awareness
of the alarm symptoms indicating the presence and complications of
spinal metastases and by setting clear deadlines for the appropriate and
timely diagnosis and treatment of spinal metastases. This aids in pre-
venting – as much as possible – debilitating clinical symptoms such as
progressive pain, spinal instability, and/or neurological deﬁcits.
In the guideline, we emphasize a proactive treatment of epidural
metastases; however, the initiation of every treatment occurs after a
patient complains of one or more symptoms. Ideally, treatment would
begin just before such complaints occur, but we are not currently aware
of a modality to predict who will suﬀer from symptomatic metastases.
Screening everyone with a malignant cancer diagnosis for spinal epi-
dural metastasis will not contribute to an increased quality of life and is
certainly not cost-eﬀective. The possibility of predicting spinal metas-
tases could be a very interesting topic on which to focus future research.
The education of patients and clinicians, both hospital specialists
and GPs, should focus on recognizing the alarm symptoms. We have
published parts of the results of the Dutch guideline in a Dutch general
medical journal that targets a broad audience, thereby educating clin-
icians and raising awareness about the alarm symptoms and the ex-
istence of the new Dutch guideline [59,60].
Distributing information on the presence and complications of
spinal metastases is challenging, as patients with cancer are seen by and
treated in numerous institutes and by various clinicians, including GPs.
It therefore requires inter-institution and interdisciplinary commu-
nication between clinicians, with clear agreements on who furnishes
the patient with information including the alarm symptoms. These
working arrangements, together with the patient information sheet,
should be easily accessible through a content management system.
Moreover, adopting information about the alarm symptoms on websites
for patients with cancer and supplying the information in patient in-
formation brochures for each of the involved medical specialties might
enhance the education of patients. To this end, the information for
patients has been made available online on a national website designed
for patients with cancer (www.kanker.nl), as well as on a website
comprising a database of oncology-related guidelines [15]. Finally, a
responsible physician should be accountable for ensuring that patients
are adequately informed.
Easy access to diagnostic imaging and treatment, i.e. radiotherapy
and spinal surgery facilities, should be available to enable timely di-
agnosis and treatment. The guideline sets clear and relatively tight
Table 3
Indications and deadlines for MRI scanning.
Symptom Deadline for MRI scanning
Only local back pain Within two weeks
Unilateral radicular pain Within one week
Unilateral radicular deﬁcit that develops over more
than seven days and has a progressive nature
Within 48 h
Unilateral radicular deﬁcit that develops within
seven days and has a progressive nature
Within 24 h
Clinical suspicion of MESCCa As soon as possible, but at
least within 12 h
a In the case of MESCC, treatment should start well within 24 h after MESCC
is diagnosed.
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Fig. 2. Flowchart on treatment selection in patients with symptomatic spinal metastases. MESCC: Metastatic Epidural Spinal Cord Compression. MESCC: Metastatic
Epidural Spinal Cord Compression; MRI: Magnetic Resonance Imaging.
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deadlines for diagnostics, depending on the severity of the patient’s
symptoms, and it is important that institutions maintain a policy that
allows rapid access to diagnostic imaging.
The treatment selection criteria provided in the guideline are based
on the patient’s estimated survival, degree of spinal instability, and
expected treatment outcome. To estimate survival, the prognostic
models published by Van der Linden et al. [25], Bartels et al. [42], or
Bollen et al. [11] are recommended in the guideline. It must be noted
that, although these models show comparable results, the populations
of patients with spinal metastases on which the models are based vary
greatly; for instance, the Van der Linden model contains patients with
only pain as a symptom, while about 50% of the Bollen patients had
neurological symptoms, and in the Bartels population, 84% of patients
had neurological complaints. These models have been developed and
partially validated in Dutch patients and are therefore considered to be
valid for use with Dutch patient populations. The Van der Linden model
has already been successfully validated in the Canadian population [49]
and the Bartels model has also been geographically and prospectively
validated [48,61]; nevertheless, these models should be validated fur-
ther for truly international use. These models were based on current
clinical practice; however, new treatment options are currently being
developed, and are expected to increase the survival of patients with
spinal metastases. New insights have recently been provided into the
eﬀects of tumor proﬁles and mutation status on patient survival
[62,63]; thus, existing prognostic models should be continuously up-
dated.
Although additional literature concerning the SINS has become
available since the publication of the guideline [64–67], the prospective
validation of the SINS’s predictive power to discriminate between spinal
lesions at risk of progressive debilitating instability is still lacking. In
addition, more recent studies have reported contradictory ﬁndings on
the inter- and intra-rater reliability of the SINS [52,66,68,69]; there-
fore, the guideline advises against the use of the SINS as a predictor for
progressive spinal instability. It could, however, be useful as a tool for
streamlining the communication between physicians of diﬀerent med-
ical specialties and for facilitating decision making during surgical
consultations.
With regard to the organization of care, the guideline recommends
discussing all patients with symptomatic spinal metastases in a multi-
disciplinary meeting. Weekly MC meetings already take place in several
hospitals, both academic and otherwise. For more acute situations such
as cases involving MESCC, severe pain, and/or spinal instability,
treatment must be initiated quickly, and there is usually no time to wait
for the weekly multidisciplinary meeting. In such cases, an ad hoc
consultation should be arranged, ideally in person, but a meeting over
the telephone or using more modern technologies such as Skype and the
digital transfer of PACS images oﬀer additional solutions. These tech-
nologies may also be of beneﬁt if the physicians are working in diﬀerent
institutions or at diﬀerent locations.
In addition, the guideline advises that the physician responsible for
a patient’s care should be clearly identiﬁed to both the patient and all
other caregivers, as well as being registered in the patient’s ﬁle. It is also
recommended that the responsible physician’s tasks and responsibilities
are formalized.
Ongoing initiatives are creating regional cancer networks of all
stakeholders, from GPs to tertiary referral centers (e.g., for spinal sur-
gery or radiotherapy). Within these networks, agreements on the or-
ganization, monitoring, and continuous improvement of care are being
made, ensuring that all patients in their respective geographic regions
beneﬁt from the best-quality care available. In the Netherlands for ex-
ample, regional Comprehensive Cancer Networks are being established,
while the NICE guideline describes the formation of cancer networks
within the United Kingdom.
The current guideline prescribes a prominent role for the GP in the
care of patients with spinal metastases. In the Netherlands, all citizens
are registered with a GP (also termed a family doctor or family physi-
cian) who oﬀers primary care, which is reimbursed by the patient’s
(mandatory) health insurance. As a result of this easily accessible pri-
mary care, Dutch GPs have a good overview of the health status of their
patients, can play a major role in their palliative care, and may serve as
the responsible physician; however, we acknowledge that the role of
the GP may be diﬀerent in other countries.
Conclusion
This national multidisciplinary guideline aims to improve the
quality of care for patients with cancer and spinal metastases and he-
matological malignancies and, consequently, improve their quality of
life. Four important principles are deﬁned: (1) the patient’s perspective
leads the discussion; (2) proactive management is directed at pre-
venting complications; (3) clear treatment selection criteria are deﬁned;
and (4) the organization, communication, and coordination of care is
optimized. The guideline explicitly pursues proactive, multidisciplinary
patient care and gives recommendations about diagnostics, treatment
modalities, patient selection, follow-up, organization of care, and pal-
liative care. Finally, practical considerations regarding the im-
plementation of the guideline are also discussed.
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